News Releases

April 6, 2021
Cogent Biosciences Announces Creation of Cogent Research Team
Names industry veteran John Robinson, PhD as Chief Scientific Officer New Boulder-based team with exceptional track record of drug discovery and development focused on creating novel small molecule therapies for rare, genetically driven diseases Strong year-end cash position of $242.2 million
March 16, 2021
Cogent Biosciences Reports Fourth Quarter 2020 and Full Year 2020 Financial Results
CGT9486 clinical trial initiations on-track: Advanced Systemic Mastocytosis (1H21), Non-Advanced Systemic Mastocytosis (2H21), Gastrointestinal Stromal Tumors (GIST) (2H21) Final data from CGT9486 + sunitinib Phase 1/2 study presented at CTOS 2020 demonstrated 12 months median PFS and 20% ORR,
February 22, 2021
Cogent Biosciences Appoints Accomplished Finance Executive Todd E. Shegog to its Board of Directors
CAMBRIDGE, Mass. , Feb. 22, 2021 /PRNewswire/ --  Cogent Biosciences, Inc.  (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the appointment of Todd E. Shegog to its Board of Directors.
February 18, 2021
Cogent Biosciences to Present at Virtual 10th Annual SVB Leerlink Global Healthcare Conference 2021
CAMBRIDGE, Mass. , Feb. 18, 2021 /PRNewswire/ --  Cogent Biosciences, Inc.  (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that Andrew Robbins , Chief Executive Officer and President, will present at the 10 th
February 11, 2021
Cogent Biosciences to Present at LifeSci Partners Virtual Precision Oncology Day 2021
CAMBRIDGE, Mass. , Feb. 11, 2021 /PRNewswire/ -- Cogent Biosciences , Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that Andrew Robbins , Chief Executive Officer and President, will present a corporate
The press releases contained in this archive section are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. Unum disavows any obligation to update the information contained in such press releases after the date of their issuance.